TY - JOUR
T1 - Results of the French Multicentric Study of ANACONDA™ Fenestrated Endografts in the Treatment of Complex Aortic Pathologies (EFEFA Registry)
AU - EFEFA Research Group
AU - EFEFA Research Group
AU - Midy, Dominique
AU - Becquemin, Jean Pierre
AU - Mialhe, Claude
AU - Frisch, Nicolas
AU - Martinez, Robert
AU - Caradu, Caroline
AU - Midy, Dominique
AU - Becquemin, Jean Pierre
AU - Martinez, Robert
AU - Frisch, Nicolas
AU - Mialhe, Claude
AU - Albertin, Jérôme
AU - Alimi, Yves
AU - Hartung, Olivier
AU - Koskas, Fabien
AU - Gaudric, Julien
AU - Bour, Pascal
AU - Fabre, Dominique
AU - Cardon, Alain
AU - Chakfe, Nabil
AU - Pernet, Philippe
AU - Skowronski, Pawel
AU - Malikov, Sergueï
AU - Canaud, Ludovic
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017
Y1 - 2017
N2 - Background Most of the experience on fenestrated endovascular aneurysm repair involves the custom-made Zenith® endograft (Cook). The fenestrated Anaconda® endograft (Vascutek) was introduced with the potential advantages of complete repositioning and lack of stent material on the main aortic body for more versatility. However, few data are available. Our objective was to assess its mid-term results in the treatment of complex aortic aneurysms. Methods Consecutive patients treated with the custom-made fenestrated Anaconda endograft in France and the Principality of Monaco, from December 2010 to October 2015, were included. Results Eighty-six patients were included over 16 centers (82 men, mean age 73.4 ± 8.1 years, 16 (18.6%) symptomatic aneurysms). The repositioning system was used in 68 cases (79.1%). Two hundred ninety-two visceral/renal vessels were targeted, with a mean number of 3.4 ± 0.6 target vessels/patient and a successful reconstruction in 99.3% of the cases (290/292 vessels). Perioperative technical success was achieved in 86.0% (74/86 patients). In-hospital and 30-day mortality rates were 3.5% (3 patients) and 7.0% (6 patients), respectively. At 12 and 24 months, estimated overall survival rate was 88.3% and 85.2%, target vessel's patency rate was 97.2% and 96.3%, and freedom from aneurysm-related reintervention rate was 96.3% and 88.0%, respectively. At 24 months, there were 7 type II endoleaks (12.7%) and a significant reduction in aneurysm maximum transverse diameter in 70.4%. Five limb occlusions occurred at 1-year and 1 at 2-year follow-up (7.0%). Conclusions The fenestrated Anaconda stent-graft system offers acceptable technical success rates, mid-term efficacy, and durability with respect to aneurysm sac regression, target vessel patency, overall mortality, and reintervention rates. Long-term results are still awaited, until then, the rate of graft limb occlusion is of concern and should be further investigated, especially in case of particularly complex aortic anatomies.
AB - Background Most of the experience on fenestrated endovascular aneurysm repair involves the custom-made Zenith® endograft (Cook). The fenestrated Anaconda® endograft (Vascutek) was introduced with the potential advantages of complete repositioning and lack of stent material on the main aortic body for more versatility. However, few data are available. Our objective was to assess its mid-term results in the treatment of complex aortic aneurysms. Methods Consecutive patients treated with the custom-made fenestrated Anaconda endograft in France and the Principality of Monaco, from December 2010 to October 2015, were included. Results Eighty-six patients were included over 16 centers (82 men, mean age 73.4 ± 8.1 years, 16 (18.6%) symptomatic aneurysms). The repositioning system was used in 68 cases (79.1%). Two hundred ninety-two visceral/renal vessels were targeted, with a mean number of 3.4 ± 0.6 target vessels/patient and a successful reconstruction in 99.3% of the cases (290/292 vessels). Perioperative technical success was achieved in 86.0% (74/86 patients). In-hospital and 30-day mortality rates were 3.5% (3 patients) and 7.0% (6 patients), respectively. At 12 and 24 months, estimated overall survival rate was 88.3% and 85.2%, target vessel's patency rate was 97.2% and 96.3%, and freedom from aneurysm-related reintervention rate was 96.3% and 88.0%, respectively. At 24 months, there were 7 type II endoleaks (12.7%) and a significant reduction in aneurysm maximum transverse diameter in 70.4%. Five limb occlusions occurred at 1-year and 1 at 2-year follow-up (7.0%). Conclusions The fenestrated Anaconda stent-graft system offers acceptable technical success rates, mid-term efficacy, and durability with respect to aneurysm sac regression, target vessel patency, overall mortality, and reintervention rates. Long-term results are still awaited, until then, the rate of graft limb occlusion is of concern and should be further investigated, especially in case of particularly complex aortic anatomies.
UR - http://www.scopus.com/inward/record.url?scp=85020742977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020742977&partnerID=8YFLogxK
U2 - 10.1016/j.avsg.2017.03.171
DO - 10.1016/j.avsg.2017.03.171
M3 - Article
C2 - 28495540
AN - SCOPUS:85020742977
SN - 0890-5096
VL - 43
SP - 151
EP - 165
JO - Annals of Vascular Surgery
JF - Annals of Vascular Surgery
ER -